SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark Life Scienc - Quaterly Results

20 Oct 2023 Evaluate
The company witnessed a 16.90% growth in the revenue at Rs. 5953.63 millions for the quarter ended September 2023 as compared to Rs. 5092.99 millions during the year-ago period.A humble growth in net profit of 11.10% reported in the quarter ended September 2023 to Rs. 1187.37  millions from Rs. 1068.78 millions.Operating profit for the quarter ended September 2023 rose to 1724.53 millions as compared to 1536.59 millions of corresponding quarter ended September 2022.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202309 202209 % Var 202309 202209 % Var 202303 202203 % Var
Sales 5953.63 5092.99 16.90 11738.13 9991.69 17.48 21612.20 21232.14 1.79
Other Income 53.69 100.20 -46.42 72.20 195.13 -63.00 289.57 147.04 96.93
PBIDT 1724.53 1536.59 12.23 3674.65 3099.20 18.57 6712.50 6307.64 6.42
Interest 3.99 1.33 200.00 7.95 2.68 196.64 5.47 279.62 -98.04
PBDT 1720.54 1535.26 12.07 3666.70 3096.52 18.41 6707.03 6028.02 11.26
Depreciation 131.29 99.35 32.15 257.41 198.14 29.91 420.94 378.77 11.13
PBT 1589.25 1435.91 10.68 3409.29 2898.38 17.63 6286.09 5649.25 11.27
TAX 401.88 367.13 9.47 867.42 742.27 16.86 1616.48 1462.01 10.57
Deferred Tax 14.88 28.20 -47.23 44.43 41.05 8.23 110.37 85.74 28.73
PAT 1187.37 1068.78 11.10 2541.87 2156.11 17.89 4669.61 4187.24 11.52
Equity 245.05 245.05 0.00 245.05 245.05 0.00 245.05 245.05 0.00
PBIDTM(%) 28.97 30.17 -3.99 31.31 31.02 0.93 31.06 29.71 4.55

Alivus Life Sciences Share Price

1066.65 -6.50 (-0.61%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×